Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy

Liisa M. Hirvonen, Gilbert O. Fruhwirth, Nishanthan Srikantha, Matthew J. Barber, James E. Neffendorf, Klaus Suhling, Timothy L. Jackson

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)

Abstract

Purpose: To measure the hydrodynamic radii of intravitreal anti-VEGF drugs ranibizumab, aflibercept and bevacizumab with μs time-resolved phosphorescence anisotropy. Methods: Ruthenium-based dye Ru(bpy)2(mcbpy − O − Su − ester)(PF6)2, whose lifetime of several hundred nanoseconds is comparable to the rotational correlation time of these drugs in buffer, was used as a label. The hydrodynamic radii were calculated from the rotational correlation times of the Ru(bpy)2(mcbpy − O − Su − ester)(PF6)2-labelled drugs obtained with time-resolved phosphorescence anisotropy measurements in buffer/glycerol solutions of varying viscosity. Results: The measured radii of 2.76±0.04 nm for ranibizumab, 3.70±0.03 nm for aflibercept and 4.58±0.01 nm for bevacizumab agree with calculations based on molecular weight and other experimental measurements. Conclusions: Time-resolved phosphorescence anisotropy is a relatively simple and straightforward method that allows experimental measurement of the hydrodynamic radius of individual proteins, and is superior to theoretical calculations which cannot give the required accuracy for a particular protein.

Original languageEnglish
Pages (from-to)2025-2032
Number of pages8
JournalPharmaceutical Research
Volume33
Issue number8
DOIs
Publication statusPublished - 1 Aug 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy'. Together they form a unique fingerprint.

Cite this